Show simple item record

dc.contributor.authorFaller, Eamonn
dc.contributor.authorWyse, Adrianne
dc.contributor.authorBarry, Rachel
dc.contributor.authorConlon, Kevin
dc.contributor.authorEverard, Cormac
dc.contributor.authorFinnegan, Paula
dc.contributor.authorForan, Claire
dc.contributor.authorHerlihy, Emer
dc.contributor.authorKerr, Gerry
dc.contributor.authorLapthorne, Susan
dc.contributor.authorMcGreal-Bellone, Aimee
dc.contributor.authorMorrissey, Edmond
dc.contributor.authorO'Sullivan, Deirdre
dc.contributor.authorO'Sullivan, Grainne
dc.contributor.authorEustace, Joseph A
dc.contributor.authorSpillane, Declan
dc.contributor.authorDempsey, Catherine
dc.contributor.authorBenson, John
dc.contributor.authorPrentice, Mike
dc.contributor.authorGallagher, John
dc.contributor.authorMacSharry, John
dc.contributor.authorFanning, Liam J
dc.contributor.authorO'Riordan, Stephen
dc.contributor.authorHorgan, Mary
dc.contributor.authorSadlier, Corinna
dc.date.accessioned2021-12-03T11:55:30Z
dc.date.available2021-12-03T11:55:30Z
dc.date.issued2021-06-08
dc.identifier.pmid34103324
dc.identifier.doi10.1136/bmjopen-2021-051415
dc.identifier.urihttp://hdl.handle.net/10147/630756
dc.description.abstractObjective: This study investigated seroprevalence of SARS-CoV-2-specific IgG antibodies, using the Abbott antinucleocapsid IgG chemiluminescent microparticle immunoassay (CMIA) assay, in five prespecified healthcare worker (HCW) subgroups following the first wave of the COVID-19 pandemic. Setting: An 800-bed tertiary-level teaching hospital in the south of Ireland. Participants: Serum was collected for anti-SARS-CoV-2 nucleocapsid IgG using the Abbott ARCHITECT SARS-CoV-2 IgG CMIA qualitative assay, as per the manufacturer's specifications.The groups were as follows: (1) HCWs who had real-time PCR (RT-PCR) confirmed COVID-19 infection (>1-month postpositive RT-PCR); (2) HCWs identified as close contacts of persons with COVID-19 infection and who subsequently developed symptoms (virus not detected by RT-PCR on oropharyngeal/nasopharyngeal swab); (3) HCWs identified as close contacts of COVID-19 cases and who remained asymptomatic (not screened by RT-PCR); (4) HCWs not included in the aforementioned groups working in areas determined as high-risk clinical areas; and (5) HCWs not included in the aforementioned groups working in areas determined as low-risk clinical areas. Results: Six of 404 (1.49%) HCWs not previously diagnosed with SARS-CoV-2 infection (groups 2-5) were seropositive for SARS-CoV-2 at the time of recruitment into the study.Out of the 99 participants in group 1, 72 had detectable IgG to SARS-CoV-2 on laboratory testing (73%). Antibody positivity correlated with shorter length of time between RT-PCR positivity and antibody testing.Quantification cycle value on RT-PCR was not found to be correlated with antibody positivity. Conclusions: Seroprevalence of SARS-CoV-2 antibodies in HCWs who had not previously tested RT-PCR positive for COVID-19 was low compared with similar studies.en_US
dc.language.isoenen_US
dc.rights© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
dc.subjectCOVID-19en_US
dc.subjectdiagnostic microbiologyen_US
dc.subjectEPIDEMIOLOGYen_US
dc.subjectINFECTION CONTROLen_US
dc.titleSeroprevalence study of SARS-CoV-2 antibodies in healthcare workers following the first wave of the COVID-19 pandemic in a tertiary-level hospital in the south of Ireland.en_US
dc.typeArticleen_US
dc.typeOtheren_US
dc.identifier.eissn2044-6055
dc.identifier.journalBMJ openen_US
dc.description.peer-reviewpeer-reviewen_US
dc.source.journaltitleBMJ open
dc.source.volume11
dc.source.issue6
dc.source.beginpagee051415
dc.source.endpage
refterms.dateFOA2021-12-03T11:55:31Z
dc.source.countryEngland


Files in this item

Thumbnail
Name:
e051415.full.pdf
Size:
532.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record